跳至主要内容
临床试验/JPRN-UMIN000005637
JPRN-UMIN000005637已完成未知

An Open Label Study Comparing the Clinical Equivalence of Generic Pioglitazone Hydrochloride 15mg tablets (SAWAI) and ACTOS 15mg tablets - Clinical Equivalence of Generic Pioglitazone Hydrochloride 15mg tablets (SAWAI) and ACTOS 15mg tablets

Tokyo-Eki Center-building Clinic0 个研究点目标入组 50 人开始时间: 2011年5月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • History and/or complication of cardiac failure. Need of insulin therapy. Treated using three or more oral anti-diabetes drugs other than ACTOS tablets 15. Renal or liver dysfunction. Complication with or recent history of myocardial infarction, angina pectoris, cerebral stroke, and cerebral infarction. Malignant neoplasms. Severe ketosis, diabetic coma. History of hypersensitive reaction to pioglitazone. History of major gastrointestinal surgery. Pregnancy. History of alcohol abuse.

研究者

相似试验